ReviewBrain pathology (Zurich, Switzerland)2013
α-Synuclein: the long distance runner.
Review in Brain pathology (Zurich, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress.Journal of Parkinson's disease · 2017Trial
- Impairment of the intracranial lymphatic system in Parkinson's disease: a combined study of the meningeal lymphatics vessels and glymphatic system based on noninvasive neuroimaging.European journal of medical research · 2025Article
- Parkinson's disease with possible REM sleep behavior disorder correlated with more severe glymphatic system dysfunction.NPJ Parkinson's disease · 2025Article
- PET tracer development for imaging α-synucleinopathies.Archives of pharmacal research · 2025Review
- Chronic DSS-Induced Colitis Exacerbates Parkinson's Disease Phenotype and Its Pathological Features Following Intragastric Rotenone Exposure.ACS pharmacology & translational science · 2025Article
- Article
- Development of Small Molecules Targeting α-Synuclein Aggregation: A Promising Strategy to Treat Parkinson's Disease.Pharmaceutics · 2023Review
- The Role of Alpha-Synuclein Deposits in Parkinson's Disease: A Focus on the Human Retina.International journal of molecular sciences · 2023Review
- Propagation of Distinct α-Synuclein Strains Within Human Reconstructed Neuronal Network and Associated Neuronal Dysfunctions.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Common mechanisms underlying axonal transport deficits in neurodegenerative diseases: a mini review.Frontiers in molecular neuroscience · 2023Review
- Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management.NPJ Parkinson's disease · 2022Review
- Postganglionic Sudomotor Assessment in Early Stage of Multiple System Atrophy and Parkinson Disease: A Morpho-functional Study.Neurology · 2022Article
- Alpha-synuclein alters the faecal viromes of rats in a gut-initiated model of Parkinson's disease.Communications biology · 2021Article
- Pharmacophore modeling and 3D-QSAR study for the design of novel α-synuclein aggregation inhibitors.Journal of molecular modeling · 2021Article
- Diffusion Tensor Imaging Along the Perivascular Space Index in Different Stages of Parkinson's Disease.Frontiers in aging neuroscience · 2021Article
- Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson's Disease.Frontiers in neuroscience · 2021Review
- The human olfactory system in two proteinopathies: Alzheimer's and Parkinson's diseases.Translational neurodegeneration · 2020Review
- Pathogenic Mutations Differentially Regulate Cell-to-Cell Transmission of α-Synuclein.Frontiers in cellular neuroscience · 2020Article
- α-Synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb.Acta neuropathologica communications · 2019Article
- Skin nerve α-synuclein deposits in Parkinson's disease and other synucleinopathies: a review.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease is characterized by α-synuclein pathology in the form of Lewy bodies and Lewy neurites. Braak et al described the spatial and temporal spread of α-synuclein pathology in Parkinson's disease. Recent experimental studies have demonstrated that α-synuclein can transfer from cell to cell. In this review, we highlight the involvement of α-synuclein in Parkinson's disease and in Braak's staging of Parkinson's disease pathology. We discuss whether a prion-like mechanism of α-synuclein spread might contribute to Parkinson's disease pathology. We describe recent studies investigating cell-to-cell transfer of α-synuclein and focus our review on the long-distance axonal transport of α-synuclein along neurons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.